Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

Abstract: Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Methods and systems are disclosed for quickly providing Whois services to a new top level domain after it is provisioned in a registry. In one embodiment, domain data is received at a first system regarding a top level domain (TLD). The domain data is assigned an authoritative port of a Whois server and is provisioned in a registry database. In certain embodiments, the Whois server provides information relating to domain name registrations of the TLD in the database, according to the authoritative port. The Whois server determines that a Whois query is received at the authoritative port for the queried TLD and responds with the queried information. To the requester, the responses appear as if they are sent from a unique Whois server for each TLD, but the Whois server is actually shared among the TLDs.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Methods and systems are disclosed for quickly providing Whois services to a new top level domain after it is provisioned in a registry. In one embodiment, domain data is received at a first system regarding a top level domain (TLD). The domain data is assigned an authoritative port of a Whois server and is provisioned in a registry database. In certain embodiments, the Whois server provides information relating to domain name registrations of the TLD in the database, according to the authoritative port. The Whois server determines that a Whois query is received at the authoritative port for the queried TLD and responds with the queried information. To the requester, the responses appear as if they are sent from a unique Whois server for each TLD, but the Whois server is actually shared among the TLDs.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Methods and systems are disclosed for quickly providing Whois services to a new top level domain after it is provisioned in a registry. In one embodiment, domain data is received at a first system regarding a top level domain (TLD). The domain data is assigned an authoritative port of a Whois server and is provisioned in a registry database. In certain embodiments, the Whois server provides information relating to domain name registrations of the TLD in the database, according to the authoritative port. The Whois server determines that a Whois query is received at the authoritative port for the queried TLD and responds with the queried information. To the requester, the responses appear as if they are sent from a unique Whois server for each TLD, but the Whois server is actually shared among the TLDs.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Methods and systems are disclosed for quickly providing Whois services to a new top level domain after it is provisioned in a registry. In one embodiment, domain data is received at a first system regarding a top level domain (TLD). The domain data is assigned an authoritative port of a Whois server and is provisioned in a registry database. In certain embodiments, the Whois server provides information relating to domain name registrations of the TLD in the database, according to the authoritative port. The Whois server determines that a Whois query is received at the authoritative port for the queried TLD and responds with the queried information. To the requester, the responses appear as if they are sent from a unique Whois server for each TLD, but the Whois server is actually shared among the TLDs.

Abstract: Methods and systems are disclosed for quickly providing Whois services to a new top level domain after it is provisioned in a registry. In one embodiment, domain data is received at a first system regarding a top level domain (TLD). The domain data is assigned an authoritative port of a Whois server and is provisioned in a registry database. In certain embodiments, the Whois server provides information relating to domain name registrations of the TLD in the database, according to the authoritative port. The Whois server determines that a Whois query is received at the authoritative port for the queried TLD and responds with the queried information. To the requester, the responses appear as if they are sent from a unique Whois server for each TLD, but the Whois server is actually shared among the TLDs.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.